N. Iscoe

发表

Free-standing health care facilities: financial arrangements, quality assurance and a pilot study.

A. Donner, J. Lavis, J. Lomas, 1998, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

Re-evaluating the cost of outpatient cancer chemotherapy.

R. Buckman, N. Iscoe, J. Rusthoven, 1987, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

A randomized phase III trial comparing standard and high-dose pemetrexed as second-line treatment in patients with locally advanced or metastatic non-small-cell lung cancer.

S. Novello, P. Zatloukal, N. Iscoe, 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

Phase I trial of radiation with concurrent and consolidation pemetrexed and cisplatin in patients with unresectable stage IIIA/B non-small-cell lung cancer.

A. Bezjak, F. Shepherd, S. Pearson, 2011, International journal of radiation oncology, biology, physics.

Avelumab in unresectable/metastatic, progressive, grade 2-3 neuroendocrine neoplasms (NENs): Combined results from NET-001 and NET-002 trials.

J. Hallet, N. Iscoe, C. Law, 2022, European journal of cancer.

An East Asian subgroup analysis of PROCLAIM, a phase III trial of pemetrexed and cisplatin or etoposide and cisplatin plus thoracic radiation therapy followed by consolidation chemotherapy in locally advanced nonsquamous non–small cell lung cancer

M. Ahn, Yi-long Wu, M. Orlando, 2016, Asia-Pacific journal of clinical oncology.

PROCLAIM: A phase III study of pemetrexed, cisplatin, and radiation therapy followed by consolidation pemetrexed versus etoposide, cisplatin, and radiation therapy followed by consolidation cytotoxic chemotherapy of choice in locally advanced stage III non-small-cell lung cancer of other than predom

E. Vokes, S. Senan, N. Iscoe, 2009, Clinical lung cancer.

Continuous narcotic infusion with patient-controlled analgesia for chronic cancer pain in outpatients.

N. Iscoe, I. Kerr, C. DeAngelis, 1988, Annals of internal medicine.

Temporal trends in breast cancer surgery in Ontario: can one randomized trial make a difference?

Gerrit, C. Naylor, J. Williams, 1994, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

We may get this horse to water, but will it drink?

N. Iscoe, 1998, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

Prostate cancer: 10. Palliative care.

E. Bruera, N. Iscoe, R. Choo, 1999, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

Prostate cancer screening: waiting for Godot.

N. Iscoe, 1998, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

Radiation Therapy Quality Assurance (RTQA) of Concurrent Chemoradiation Therapy for Locally Advanced Non-Small Cell Lung Cancer in the PROCLAIM Phase 3 Trial.

S. Senan, F. Wenz, A. Brade, 2018, International journal of radiation oncology, biology, physics.

A phase II study of methotrexate, vinblastine, doxorubicin and cisplatin plus recombinant human granulocyte-macrophage colony stimulating factors in patients with advanced transitional cell carcinoma.

I. Tannock, M. Moore, N. Iscoe, 1993, The Journal of urology.

Long-term outcome of postorchiectomy surveillance for Stage I testicular seminoma.

L. Klotz, C. Danjoux, N. Iscoe, 2005, International journal of radiation oncology, biology, physics.

Phase II study of trimetrexate in malignant melanoma: A National Cancer Institute of Canada Clinical Trials Group Study

E. Eisenhauer, N. Iscoe, A. Bodurtha, 1990, Investigational New Drugs.

A phase II study of weekly edatrexate (10-EDAM) in metastatic melanoma. A National Cancer Institute of Canada Clinical Trials Group study.

E. Eisenhauer, N. Iscoe, I. Quirt, 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

Extragonadal germ cell tumors. A 14‐year Toronto experience

R. Ginsberg, F. Shepherd, P. Goss, 1994, Cancer.

Enhanced viral and tumor immunity with intranodal injection of canary pox viruses expressing the melanoma antigen, gp100

T. Vogel, I. Astsaturov, D. Spaner, 2006, Cancer.

MIB-1 proliferative activity is a significant prognostic factor in primary thick cutaneous melanomas.

L. From, N. Iscoe, H. Kahn, 1995, The Journal of investigative dermatology.

Systematic review of systemic adjuvant therapy for patients at high risk for recurrent melanoma

D. McCready, N. Iscoe, I. Quirt, 2006, Cancer.

Prostate cancer screening in the midst of controversy: Canadian men's knowledge, beliefs, utilization, and future intentions.

Shawna L. Mercer, S. Mercer, D. Iverson, 1997, Canadian journal of public health = Revue canadienne de sante publique.

Amplification of virus-induced antimelanoma T-cell reactivity by high-dose interferon-alpha2b: implications for cancer vaccines.

I. Astsaturov, D. Spaner, N. Iscoe, 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

A phase II study of biweekly pemetrexed and gemcitabine in patients with metastatic breast cancer

S. Gertler, C. Canil, S. Dent, 2010, Cancer Chemotherapy and Pharmacology.

Predictive value of staging investigations in patients with clinical stage I malignant melanoma.

D. Osoba, L. From, G. Deboer, 1987, Plastic and reconstructive surgery.

The value of staging and serial follow‐up investigations in patients with completely resected, primary, cutaneous malignant melanoma

D. Osoba, L. From, G. Deboer, 1985, The British journal of surgery.

Venous access ports.

N. Iscoe, I. Kerr, M. Sone, 1985, Annals of internal medicine.

PROCLAIM: Randomized Phase III Trial of Pemetrexed-Cisplatin or Etoposide-Cisplatin Plus Thoracic Radiation Therapy Followed by Consolidation Chemotherapy in Locally Advanced Nonsquamous Non-Small-Cell Lung Cancer.

R. Govindan, H. Choy, T. Mok, 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group.

B. Zee, N. Iscoe, I. Quirt, 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A phase I study of concurrent pemetrexed (P)/cisplatin (C)/radiation (RT) for unresectable stage IIIA/B non-small cell lung cancer (NSCLC)

G. Pond, A. Bezjak, F. Shepherd, 2008 .

The Impact of Staging by Positron‐Emission Tomography on Overall Survival and Progression‐Free Survival in Patients With Locally Advanced NSCLC

R. Govindan, E. Vokes, S. Senan, 2018, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II Study of Concurrent Pemetrexed, Cisplatin, and Radiation Therapy for Stage IIIA/B Unresectable Non-Small Cell Lung Cancer.

A. Bezjak, F. Shepherd, A. Hope, 2016, Clinical lung cancer.

Phase II, Double-Blinded, Randomized Study of Enzastaurin Plus Pemetrexed as Second-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer

G. Bepler, G. Scagliotti, Keunchil Park, 2010, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Phase II, double-blind, randomized trial of capecitabine plus enzastaurin versus capecitabine plus placebo in patients with metastatic or recurrent breast cancer after prior anthracycline and taxane therapy

K. Gelmon, M. Clemons, J. Lynch, 2010, Breast Cancer Research and Treatment.

Trends in Hormonal Management of Prostate Cancer:: A Population-Based Study in Ontario

G. Browman, N. Fleshner, S. Bondy, 2001, Medical care.

The evaluation of analgesic effects in cancer patients as exemplified by a double-blind, crossover study of immediate-release versus controlled-release morphine.

P. Band, N. Iscoe, J. Rusthoven, 1992, Journal of pain and symptom management.

Variation in breast cancer surgery in Ontario.

C. Naylor, V. Goel, E. Holowaty, 1994, CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne.

A 3-week gemcitabine-cisplatin regimen for metastatic urothelial cancer.

D. Jonker, E. Winquist, N. Iscoe, 2004, The Canadian journal of urology.

Results of a survey of Canadian men with prostate cancer.

L. Klotz, R. Gray, M. Fitch, 1997, The Canadian journal of urology.